Altered glucose metabolism in pregnancy

Graves, William K.; Neff, Robert A.; Mark, Peter J.

doi:10.1016/0002-9378(67)90171-8

Cited by 8 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in perinatal loss w i t h duration of diabetes is in keeping with the findings of Graves et al (1967). Table 3 shows the excretion of oestriol in relation to the severity of diabetes.…”

Section: %supporting

confidence: 79%

Oestriol Excretion in the Pregnancy Complicated by Diabetes Mellitus

Evans

Taft

Rome

et al. 1972

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Urinary oestriol excretion was studied throughout 93 diabetic pregnancies. Low levels of excretion (38% ) were common to all clinical categories of diabetes and were not influenced by either the duration or severity of the disease.The overalI perinatal loss was 13%; the incidence was 7% in patients with normal excretion values and 23% in those with low values. Six of the 8 deaths associated with low oestriol excretion occurred after birth and all were due to the respiratory distress syndrome. Low assays may warn of impending intra-uterine death, but intervention may not be possible. A normal excretion level should not, however, permit a complacent attitude.

show abstract

Section: %supporting

confidence: 79%

Oestriol Excretion in the Pregnancy Complicated by Diabetes Mellitus

Evans

Taft

Rome

et al. 1972

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…Pioneering studies indicated that PBN blocks the transport of neurotransmitter metabolites, including homovanillic acid (HVA, dopamine), vanillyl-mandelic acid (VMA, catecholamines), and 5-hydroxy indoleacetic acid (5-HIAA, serotonin) from the cerebrospinal fluid (CSF) to circulating blood, which limits their subsequent excretion in urine [ 23 , 24 , 25 , 26 ]. These findings lead to the use of PBN as a clinical test for studies of depression [ 27 , 28 ].…”

Section: Probenecid’s Pharmacological Targetsmentioning

confidence: 99%

Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation

et al. 2023

View full text Add to dashboard Cite

Probenecid is an old uricosuric agent used in clinics to treat gout and reduce the renal excretion of antibiotics. In recent years, probenecid has gained attention due to its ability to interact with membrane proteins such as TRPV2 channels, organic anion transporters, and pannexin 1 hemichannels, which suggests new potential therapeutic utilities in medicine. Some current functions of probenecid include their use as an adjuvant to increase the bioavailability of several drugs in the Central Nervous System (CNS). Numerous studies also suggest that this drug has important neuroprotective, antiepileptic, and anti-inflammatory properties, as evidenced by their effect against neurological and neurodegenerative diseases. In these studies, the use of probenecid as a Panx1 hemichannel blocker to reduce neuroinflammation is highlighted since neuroinflammation is a major trigger for diverse CNS alterations. Although the clinical use of probenecid has declined over the years, advances in its use in preclinical research indicate that it may be useful to improve conventional therapies in the psychiatric field where the drugs used have a low bioavailability, either because of a deficient passage through the blood–brain barrier or a high efflux from the CNS or also a high urinary clearance. This review summarizes the history, pharmacological properties, and recent research uses of probenecid and discusses its future projections as a potential pharmacological strategy to intervene in neurodegeneration as an outcome of neuroinflammation.

show abstract